1. Home
  2. MTLS vs DCTH Comparison

MTLS vs DCTH Comparison

Compare MTLS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Materialise NV

MTLS

Materialise NV

HOLD

Current Price

$5.89

Market Cap

311.1M

Sector

Technology

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$9.53

Market Cap

323.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTLS
DCTH
Founded
1990
1988
Country
US
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
311.1M
323.1M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
MTLS
DCTH
Price
$5.89
$9.53
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
110.0K
450.9K
Earning Date
01-01-0001
04-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
68.37
EPS
N/A
0.12
Revenue
N/A
N/A
Revenue This Year
$2.47
$132.21
Revenue Next Year
$6.98
$35.72
P/E Ratio
$61.39
$78.92
Revenue Growth
N/A
N/A
52 Week Low
$3.93
$8.12
52 Week High
$6.80
$18.23

Technical Indicators

Market Signals
Indicator
MTLS
DCTH
Relative Strength Index (RSI) 58.08 45.88
Support Level $5.35 $8.94
Resistance Level $5.68 $9.65
Average True Range (ATR) 0.24 0.49
MACD 0.03 -0.03
Stochastic Oscillator 99.34 45.00

Price Performance

Historical Comparison
MTLS
DCTH

About MTLS Materialise NV

Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: